Polyphor signs merger agreement with EnBiotix. The advisors

EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in exchange for Polyphor Shares was signed.  Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange. 

EnBiotix is also acquiring inhaled murepavadin for an agreed value of USD 10 million in exchange for 2,599,655 common shares of EnBiotix. The completion of the merger creates a late-stage clinical development company with two clinical programs for the treatment of cystic fibrosis (CF). 

The merger is expected to close in the fourth quarter of this year. Completion of merger agreement subject to a number of closing conditions including shareholders’ consent of both companies.

The advisors

Vischer acts as legal counsel to Polyphor. The team is led by partner Matthias Staehelin (pictured) with partner Christian Wyss, partner David Jenny and senior associate Luzius Zumstein (all corporate/m&a), partner Marc Prinz (labor law) and partner Nadia Tarolli (taxes). 

Walder Wyss advises Enbiotix on this transaction. The Walder Wyss team was led by Alexander Gutmans (partner, corporate/m&a and venture capital, pictured left) and included Alex Nikitine (partner, corporate/m&a), Michelle Bruni (associate, corporate/m&a and tax), Daniel Dedeyan (counsel, banking and finance) and Karina Tschon (associate, corporate/m&a and venture capital).

 

 

 

 

FabioAdmin

SHARE